W J van der Vijgh
Overview
Explore the profile of W J van der Vijgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
2189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacobs H, Koek G, Peters R, Moalin M, Tack J, van der Vijgh W, et al.
Clin Pharmacol Ther
. 2011 Nov;
90(6):852-9.
PMID: 22048223
Despite its well-known cardiotoxicity, the anthracycline doxorubicin continues to be a widely used chemotherapeutic agent. The flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) has shown protection against doxorubicin-induced cardiotoxicity in mice. However, this protection...
2.
van Acker F, Hulshof J, Haenen G, Menge W, van der Vijgh W, Bast A
Free Radic Biol Med
. 2001 Jun;
31(1):31-7.
PMID: 11425487
A series of 3,7-disubstituted-2(3',4'-dihydroxyphenyl) flavones has been studied as potential cardioprotective agents in doxorubicin antitumor therapy. The influence of substituents on the 3 and 7 position of the flavone nucleus...
3.
Abou El Hassan M, Kedde M, Bast A, van der Vijgh W
J Chromatogr B Biomed Sci Appl
. 2001 Jun;
757(1):191-6.
PMID: 11419744
7-Monohydroxyethylrutoside (monoHER) is one of the components of the registered drug Venoruton. It showed a good protection against the cardiotoxic effects of doxorubicin. The analysis of monoHER was developed to...
4.
van Acker F, Boven E, Kramer K, Haenen G, Bast A, van der Vijgh W
Clin Cancer Res
. 2001 May;
7(5):1378-84.
PMID: 11350909
The flavonoid 7-monohydroxyethylrutoside (monoHER) can protect against doxorubicin-induced cardiotoxicity. A drawback of monoHER therapy would be the relatively high dose needed to obtain complete protection (500 mg/kg in mice). Therefore,...
5.
Verschraagen M, Zwiers T, de Koning P, Welink J, van der Vijgh W
J Chromatogr B Biomed Sci Appl
. 2001 May;
753(2):293-302.
PMID: 11334343
A sensitive and accurate assay was developed and validated to determine BNP7787 (dimesna), a new protector against cisplatin-induced toxicities, and its metabolite mesna in plasma and urine of patients. Both...
6.
Heijnen C, Haenen G, van Acker F, van der Vijgh W, Bast A
Toxicol In Vitro
. 2001 Mar;
15(1):3-6.
PMID: 11259863
It has been reported that flavonoids efficiently protect against peroxynitrite toxicity. Two pharmacophores have been identified in flavonoids, namely the catechol group in ring B and the hydroxyl (OH) group...
7.
El Hassan M, Kedde M, Bast A, van der Vijgh W
J Chromatogr B Biomed Sci Appl
. 2001 Mar;
752(1):115-21.
PMID: 11254185
MonoHER (7-monohydroxyethyl rutoside) is a semisynthetic flavonoid, which can be used as a modulator for doxorubicin-induced cardiotoxicity. To study the pharmacokinetics of monoHER in mice and human an HPLC procedure...
8.
van Acker F, Van Acker S, Haenen G, Bast A, van der Vijgh W
Anticancer Res
. 2001 Feb;
20(6B):4483-7.
PMID: 11205292
Cardiotoxicity, a side-effect that can occur after treatment with an anticancer drug, has severe clinical implications. Therefore, a model is desired to screen new anticancer drugs or drug combinations for...
9.
Abou El Hassan M, Touw D, Wilhelm A, Bast A, van der Vijgh W
Int J Pharm
. 2001 Jan;
211(1-2):51-6.
PMID: 11137338
MonoHER is a semisynthetic flavonoid used successfully in modulating the cardiotoxic effect of doxorubicin but not its antitumor activity. The oral bioavailability of monoHER is <1%. Therefore, it should be...
10.
Van Moorsel C, Pinedo H, Smid K, Comijn E, Voorn D, Veerman G, et al.
Eur J Cancer
. 2000 Nov;
36(18):2420-9.
PMID: 11094319
The combination of 2',2'-difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum(II) (cisplatin, CDDP) is increasingly applied in clinical oncology. We studied the underlying mechanisms of the in vivo schedule dependency and supraadditive interaction...